Phaseline

Companies › ExoRNA Bioscience

ExoRNA Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ER2001
antisense oligonucleotide targeting huntingtin mRNA
HTTPhase 1Huntington Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07339514ER2001Phase 1Huntington DiseaseNeurologyApr 2026

Targets

HTT (1)

Companies with the same targets

Roche Alnylam Pharmaceuticals UniQure Biopharma Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.